How the EPO treats personalised healthcare patents

Personalised healthcare, or precision medicine, is an evolving field where a therapeutic treatment is tailored to an individual with a particular disease. The aim is to target the right treatment to the right patient, typically by using a diagnostic test (companion diagnostic test) for one or more biomarkers indicative of drug response.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

Patent lawyers and judges discuss lofty UPC issues in grand London venue

UK firm hires head of IP with commercial and technical nous

10x Genomics wins latest round in Parse patent dispute

‘Busiest’ US district patent judge swaps bench for private practice

How the EPO treats personalised healthcare patents

More on this story

Editor's picks

Editor's picks

More features